Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN

Tema ETFs LLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 41.0% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 60,694 shares of the company’s stock after acquiring an additional 17,638 shares during the period. Tema ETFs LLC owned 0.10% of Enliven Therapeutics worth $3,080,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Vestal Point Capital LP lifted its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares during the last quarter. Siren L.L.C. purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at $29,252,000. Affinity Asset Advisors LLC purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at $23,007,000. TCG Crossover Management LLC acquired a new stake in Enliven Therapeutics during the 2nd quarter worth $9,990,000. Finally, Duquesne Family Office LLC raised its stake in Enliven Therapeutics by 104.6% during the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after acquiring an additional 484,405 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Trading Down 1.5%

NASDAQ:ELVN opened at $57.92 on Thursday. Enliven Therapeutics, Inc. has a 12-month low of $14.78 and a 12-month high of $62.32. The stock’s 50 day simple moving average is $49.97 and its 200-day simple moving average is $40.44. The firm has a market cap of $4.24 billion, a P/E ratio of -34.68 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Research analysts forecast that Enliven Therapeutics, Inc. will post -1.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Guggenheim reduced their target price on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen cut Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. JonesTrading raised their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Mizuho lifted their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $72.67.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer directly owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. The trade was a 64.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 190,831 shares of company stock worth $10,991,723. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.